Results 41 to 50 of about 31,338 (290)

Setting up clinical and production-based biobanks in the healthcare system of the Russian Federation

Трансплантология (Москва)
Background. The therapeutic efficacy of skin grafts and various tissue equivalents in the treatment of many diseases is known. Special clinical biobanks are engaged in the procurement of such products, their processing, storage, provision of their safety
Yu. N. Lebedeva, Yu. V. Sukhanov, E. M. Fominykh, A. V. Eremeev, O. S. Rogovaya, T. A. Aleksanyan, E. A. Vorotelyak, A. V. Vasiliev   +7 more
doaj   +1 more source

Hsa-miR-1248 suppressed the proliferation, invasion and migration of colorectal cancer cells via inhibiting PSMD10

BMC Cancer, 2022
Background Lymph node metastasis (LNM) is a critical event during the colorectal cancer (CRC) development and is indicative of poor prognosis. Identification of molecular markers of LNM may facilitate better therapeutic decision-making. Methods Six pairs
Chengxing Wang, Bin Wang, Weijun Liang, Chaorong Zhou, Weixing Lin, Zijie Meng, Wanting Wu, Meimei Wu, Yuehua Liao, Xiaoping Li, Jinglin Zhao, Yaoming He   +11 more
doaj   +1 more source

Characterizing the salivary RNA landscape to identify potential diagnostic, prognostic, and follow‐up biomarkers for breast cancer

Molecular Oncology, EarlyView.
This study explores salivary RNA for breast cancer (BC) diagnosis, prognosis, and follow‐up. High‐throughput RNA sequencing identified distinct salivary RNA signatures, including novel transcripts, that differentiate BC from healthy controls, characterize histological and molecular subtypes, and indicate lymph node involvement.
Nicholas Rajan, Irina Primac, Emre Etlioglu, Laurens Debruyne, Ann Janssen, Magy Sallam, Kevin Tabury, Roel Quintens, Wiebren Tjalma, Mohammed Abderrafi Benotmane   +9 more
wiley   +1 more source

From pharmacogenetics to pharmaco-omics: Milestones and future directions

HGG Advances, 2022
The origins of pharmacogenetics date back to the 1950s, when it was established that inter-individual differences in drug response are partially determined by genetic factors.
Chiara Auwerx, Marie C. Sadler, Alexandre Reymond, Zoltán Kutalik   +3 more
doaj   +1 more source

Enhancing reuse of data and biological material in medical research : from FAIR to FAIR-Health [PDF]

, 2018
The known challenge of underutilization of data and biological material from biorepositories as potential resources formedical research has been the focus of discussion for over a decade. Recently developed guidelines for improved data availability and
Casati, Sara, Dagher, Georges, Gabriele, Anton, Holub, Petr, Kohlmayer, Florian, Koumakis, Lefteris, Kozera, Łukasz, Lavitrano, Marialuisa, Litton, Jan-Eric, Martin, Gillian M., Mendy, Maimuna, Ommen, GertJan B. van, Prasser, Fabian, Schlunder, Irene, Sezerman, Osman Ugur, Strapagiel, Dominik, Th. Mayrhofer, Michaela, Valik, Dalibor, Wutte, Andrea, Zanetti, Gianluigi, Zatloukal, Kurt   +20 more
core   +1 more source

Adenosine‐to‐inosine editing of miR‐200b‐3p is associated with the progression of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
A‐to‐I editing of miRNAs, particularly miR‐200b‐3p, contributes to HGSOC progression by enhancing cancer cell proliferation, migration and 3D growth. The edited form is linked to poorer patient survival and the identification of novel molecular targets.
Magdalena Niemira, Anna Skwarska, Karolina Chwialkowska, Agnieszka Ostrowska, Gabriela Sokolowska, Anna Zeller, Anna Erol, Andrzej Eljaszewicz, Bartosz Hanczaruk, Anna Michalska‐Falkowska, Agnieszka Tarasik, Joanna Reszec‐Gielazyn, Pawel Knapp, Marcin Moniuszko, Adam Kretowski   +14 more
wiley   +1 more source

Biobanks and data interoperability in Latin America: engendering high-quality evidence for the global research ecosystem

Frontiers in Medicine
Currently, each biobank in Latin America operates with its own set of standards for database creation and management, resulting in a lack of regional and international interoperability.
Erick Valdés, Juan Alberto Lecaros
doaj   +1 more source

Public trust and global biobank networks

BMC Medical Ethics, 2020
Background Biobanks provide an important foundation for genomic and personalised medicine. In order to enhance their scientific power and scope, they are increasingly becoming part of national or international networks.
Lisa Dive, Christine Critchley, Margaret Otlowski, Paul Mason, Miriam Wiersma, Edwina Light, Cameron Stewart, Ian Kerridge, Wendy Lipworth   +8 more
doaj   +1 more source

Constructing effective ethical frameworks for biobanking [PDF]

, 2010
This paper is about the actual and potential development of an ethics that is appropriate to the practices and institutions of biobanking, the question being how best to develop a framework within which the relevant ethical questions are first identified
Cordell, Sean, Widdows, Heather
core  

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer

Molecular Oncology, EarlyView.
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian, Sriraam Sivachandran, Melissa Galati, Brandon Ramchatesingh, Hibo Rijal, Johnny Hanna, Elena Netchiporouk, May Chergui, Margaret Redpath, Samy Abou Setah, Ivan V. Litvinov   +10 more
wiley   +1 more source